Novartis AG
NYSE:NVS

Watchlist Manager
Novartis AG Logo
Novartis AG
NYSE:NVS
Watchlist
Price: 139.77 USD 2.12%
Market Cap: 283B USD

Operating Margin
Novartis AG

33.1%
Current
27%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
33.1%
=
Operating Profit
18.6B
/
Revenue
56B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CH
Novartis AG
SIX:NOVN
212.1B CHF
33%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
496.3B USD
27%
CH
Roche Holding AG
SIX:ROG
262.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
24%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143B USD
29%
FR
Sanofi SA
PAR:SAN
100.2B EUR
24%
No Stocks Found

Novartis AG
Glance View

Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.

NVS Intrinsic Value
145.11 USD
Undervaluation 4%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
33.1%
=
Operating Profit
18.6B
/
Revenue
56B
What is the Operating Margin of Novartis AG?

Based on Novartis AG's most recent financial statements, the company has Operating Margin of 33.1%.

Back to Top